Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Clinical trial NCT06287463 · TERMINATED

Trial details

NCT number: NCT06287463
Sponsor: Deciphera Pharmaceuticals, LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor RAF Mutation RAS Mutation NF1 Mutation Non-Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma Melanoma BRAF Gene Mutation CRAF Gene Mutation Castration-Resistant Prostate Cancer (CRPC)

Start date: 2024-05-14
Primary completion: 2026-02-13
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.